Please assess the completion status of the following clinical trial:

Trial Title: Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease of more than 5 years~* Subthalamic nucleus stimulation~* Gait disorders impeding moderately to severely the activities of daily living~* gait disorders including freezing of gait~* able to walk without physical assistance~Exclusion Criteria:~* Dementia (MMSE \< 27 et score de Mattis \< 130)~* Requiring dopatherapie modification~* Requiring subthalamic stimulation parameters adaptation~* Psychiatric disorders: hallucinations, unstable thymic disorders, psychosis)~* Cardiac disorders: dysrhythmia or unstable arterial hypertension~* Unstable or severe medical illness~* intolerance or contraindication to methylphenidate

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- methylphenidate (Type: ACTIVE_COMPARATOR): methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
- placebo (Type: PLACEBO_COMPARATOR): tablets of placebo 3 time a day

Based on this trial design, predict the completion outcome and termination type (if applicable).